HK Stock Market Move | TSLP dual antibody approved for clinical use, SKB BIO-B(06990) rose over 10% in early trading, HBM HOLDINGS-B(02142) up nearly 5%.

SKB BIO-B(06990) and HBM HOLDINGS-B(02142) both rose in the early trading session. As of the time of this report, SKB Bio rose by 8.95% to 414 Hong Kong dollars, while HBM Pharmaceuticals rose by 4.26% to 12 Hong Kong dollars. On the news front, on March 9th, the CDE official website revealed that the SKB575 (HBM7575) injection jointly applied for by SKB Bio and HBM Pharmaceuticals has been approved for clinical use, intended for the treatment of atopic dermatitis. This is the first bispecific antibody to enter the clinical stage in the collaboration pipeline of the two companies in the field of autoimmune diseases. It is reported that HBM7575/SKB575 targets thymic stromal lymphopoietin (TSLP) and an undisclosed target, with dual action mechanisms. On one hand, it inhibits TSLP-mediated signaling pathways and activation of Th2 immune cells by blocking the interaction between TSLP and its receptor. On the other hand, its binding and blocking of the undisclosed target can produce a synergistic effect, overcoming the resistance issues of TSLP monotherapeutic antibodies.